Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer-Reference-Cited by-同舟云学术

Phase II trial of high-dose intravenous doxorubicin, etoposide, and cyclophosphamide with autologous stem cell support in patients with residual or responding recurrent ovarian cancer

Published:2001-11 Issue:9 Volume:28 Page:859-863
ISSN:0268-3369
Container-title:Bone Marrow Transplantation
language:en
Short-container-title:Bone Marrow Transplant

Author:

Morgan RJ,Doroshow JH,Leong L,Schriber J,Shibata S,Forman S,Hamasaki V,Margolin K,Somlo G,Alvarnas J,McNamara M,Longmate J,Raschko J,Chow W,Vasilev S,McGonigle K,Yen Y

Publisher

Springer Science and Business Media LLC

Subject

Transplantation,Hematology

Link

http://www.nature.com/articles/1703243.pdf

Reference28 articles.

1. Alberts DS, Green S, Hannigan EV et al. Improved therapeutic index of carboplatin plus cyclophosphamide versus cisplatin plus cyclophosphamide: final report by the Southwest Oncology Group of a phase III randomized trial in stages III and IV ovarian cancer J Clin Oncol 1992 10: 706–717

2. Howell SB, Zimm S, Markman M et al. Long-term survival of advanced refractory ovarian carcinoma patients with small-volume disease treated with intraperitoneal chemotherapy J Clin Oncol 1987 5: 1607–1612

3. Swenerton K, Jeffrey J, Stuart G et al. Cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in advanced ovarian cancer: a randomized phase III study of the national cancer institute of Canada clinical trials group J Clin Oncol 1992 10: 718–726

4. Hryniuk W . The importance of dose intensity in the outcome of chemotherapy. In: Hellman, S, DeVita V, Rosenberg S (eds) Important Advances in Oncology Lippincott: Philadelphia 1988 pp 121–141

5. Tepler I, Cannistra SA, Frei E et al. Use of peripheral-blood progenitor cells abrogates the myelotoxicity of repetitive outpatient high-dose carboplatin and cyclophosphamide chemotherapy J Clin Oncol 1993 11: 1583–1591

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Reversal of Resistance to Oxazaphosphorines;Current Cancer Drug Targets;2006-08-01

2. Post-operative sequential high-dose chemotherapy with haematopoietic stem cell support as front-line treatment in advanced ovarian cancer: a phase II multicentre study;Bone Marrow Transplantation;2006-02-27

3. Clinical Pharmacology of Cyclophosphamide and Ifosfamide;Current Drug Therapy;2006-01-01

4. Metabolism and Transport of Oxazaphosphorines and the Clinical Implications;Drug Metabolism Reviews;2005-01

5. Update on the Prevention and Treatment of Ovarian Cancer;Journal of Pharmacy Practice;2003-06